Fortress Biotech (Fortress Biotech) Debt-to-Equity : 3.76 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech Debt-to-Equity?

Fortress Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.52 Mil. Fortress Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $79.14 Mil. Fortress Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $22.54 Mil. Fortress Biotech's debt to equity for the quarter that ended in Dec. 2023 was 3.76.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Fortress Biotech's Debt-to-Equity or its related term are showing as below:

FBIO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.21 Med: 1.04 Max: 42.93
Current: 3.76

During the past 13 years, the highest Debt-to-Equity Ratio of Fortress Biotech was 42.93. The lowest was 0.21. And the median was 1.04.

FBIO's Debt-to-Equity is ranked worse than
97.48% of 1072 companies
in the Biotechnology industry
Industry Median: 0.145 vs FBIO: 3.76

Fortress Biotech Debt-to-Equity Historical Data

The historical data trend for Fortress Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Debt-to-Equity Chart

Fortress Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

4.39

0.89

0.69

3.05

3.76

Fortress Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															3.05	3.24	4.37	4.21	3.76

Competitive Comparison of Fortress Biotech's Debt-to-Equity

For the Biotechnology subindustry, Fortress Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fortress Biotech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Debt-to-Equity falls into.

Fortress Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Fortress Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.523	+	79.138)	/	22.544
	=	3.76

Fortress Biotech's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.523	+	79.138)	/	22.544
	=	3.76

Fortress Biotech (NAS:FBIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Fortress Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortress Biotech (Fortress Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

FBIOP.PFD:USA CNB0.PFD:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154

Website

https://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Executives

Rosenwald Lindsay A Md	director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN	375 PARK AVE, NEW YORK NY 10152
Lucy Lu	director	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin	officer: Chief Financial Officer	C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Dov Klein	director	C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Robyn Hunter	officer: Chief Financial Officer	95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky	director	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein	director	750 LEXINGTON AVENUE, NEW YORK NY 10022
Michael S Weiss	director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN	750 LEXINGTON AVE, NEW YORK NY 10022
J Jay Lobell	director	365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Jimmie Harvey	director	3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
Kevin Lorenz	director	C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos	officer: SVP, Biologics Operations	C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan	other: Former Chief Medical Officer	C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett	director	ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803